<DOC>
	<DOCNO>NCT01768026</DOCNO>
	<brief_summary>The objective study characterize extent severity disease subject DEB progression disease timeframe relevant interventional study . The data study use inform study design address statistical consideration future treatment protocol .</brief_summary>
	<brief_title>Prospective , Longitudinal Natural History Study Dystrophic Epidermolysis Bullosa</brief_title>
	<detailed_description>This prospective , multicenter , multinational , longitudinal assessment disease severity subject DEB . Subjects either dominant recessive DEB ( dominant dystrophic epidermolysis bullosa ( DDEB ) recessive dystrophic epidermolysis bullosa ( RDEB ) , respectively ) assess four time one year period : upon enrollment , 1 2 week 6 12 month enrollment . All subject either DDEB RDEB meet study entry criterion offer participation study , provide accommodate within anticipate study timeline . In addition usual clinic assessment , subject quantitative evaluation skin involvement ask fill questionnaire measure among thing disease severity , QOL , pain , pruritus , medical family history .</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
	<criteria>Eligibility Criteria Subjects age ( newborn include ) may participate Subjects 18 year age parent ( ) /legal guardian ( ) subject &lt; 18 year age must provide write informed consent prior participate study inform assent obtain minor least 7 year age Subjects must document diagnosis DEB base clinical presentation either skin biopsy result show absence reduction C7 anchor fibril genetic analysis show mutation collagen , type VII , alpha 1 ( Col7A1 ) ; alternatively , subject must clinical diagnosis DEB document diagnosis DEB ( ) first degree relative No experimental systemic therapy DEB include , limited , bone marrow transplantation , systemic immune suppression , experimental therapy involve live cell potential systemic spread gene transfer , stem cell infusion cell type injection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Dystrophic Epidermolysis Bullosa</keyword>
	<keyword>Type VII Collagen</keyword>
	<keyword>QOL Evaluation Epidermolysis Bullosa</keyword>
	<keyword>Instrument Scoring Clinical Outcomes Research Epidermolysis Bullosa</keyword>
	<keyword>Birmingham Epidermolysis Bullosa Severity Score</keyword>
</DOC>